Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma Inc (JP:4503)
:4503
Holding JP:4503?
Track your performance easily
Earnings Data
Report Date
Feb 04, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
24.53Last Year’s EPS
10.4Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: -14.60%
|Next Earnings Date:Jul 27, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed sentiment. While there were notable achievements in sales growth for products like XTANDI, XOSPATA, and PADCEV, challenges with VEOZAH's performance and operating profit declines were significant. The company has made progress in product launches and sales in key areas, but financial metrics fell short of expectations, indicating a need for strategic adjustments.Company Guidance
During the earnings call for Q3 FY 2023, Astellas Pharma Inc. provided guidance on several key metrics and outlooks. Revenue for the third quarter increased to JPY 1,189.1 billion, a 2.1% year-on-year growth, with a positive foreign exchange impact of JPY 58.8 billion. However, core operating profit dropped by 36% year-on-year to JPY 149.6 billion, partly due to the acquisition of Iveric Bio. Operating profit fell 59.1% to JPY 74.1 billion, and overall profit decreased by 65.3% to JPY 50.3 billion. The company revised its full-year revenue forecast downward by JPY 46 billion to JPY 1,562 billion, primarily due to lower-than-expected demand for VEOZAH, despite ongoing progress in market access and DTC activities. Sales for key products like XTANDI and XOSPATA showed positive trends, with XTANDI's global sales increasing by 9% year-on-year to JPY 560 billion, while XOSPATA's sales rose by 14% to JPY 41.3 billion. The potential peak sales forecast for PADCEV was revised upward to JPY 400 billion to JPY 500 billion due to robust EV-302 study results, indicating strong growth prospects for FY 2024 and beyond.Strong Performance by Key Products
XTANDI and XOSPATA sales were in line with the full year forecast. XTANDI achieved about 5% growth year-on-year, reaching JPY 560 billion sales, up by 9% year-on-year. XOSPATA global sales increased to JPY 41.3 billion, up 14% year-on-year.
PADCEV Sales Surge
PADCEV global sales increased to JPY 55.6 billion, up by 68% year-on-year, driven by market penetration in the US. Potential peak sales forecast was revised upward to JPY 400 billion to JPY 500 billion.
IZERVAY Encouraging Launch
IZERVAY sales in about 4 months since launch were JPY 5.3 billion, capturing an estimated 20% market share in the third quarter period.
---
JP:4503 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JP:4503 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | ¥1790.50 | ¥1789.00 | -0.08% |
| Aug 01, 2024 | ¥1709.89 | ¥1677.11 | -1.92% |
| Apr 25, 2024 | ¥1437.38 | ¥1423.68 | -0.95% |
| Feb 05, 2024 | ¥1609.85 | ¥1629.01 | +1.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Astellas Pharma Inc (JP:4503) report earnings?
Astellas Pharma Inc (JP:4503) is schdueled to report earning on Feb 04, 2025, TBA Not Confirmed.
What is Astellas Pharma Inc (JP:4503) earnings time?
Astellas Pharma Inc (JP:4503) earnings time is at Feb 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Astellas Pharma Inc stock?
The P/E ratio of Astellas Pharma is N/A.
What is JP:4503 EPS forecast?
JP:4503 EPS forecast for the fiscal quarter 2024 (Q3) is 24.53.
---